GlassScriptPhysician profile
Harold A Condara
NPI 1891799144
$3,606.00
in general payments reported to CMS, 2019-2025
23 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $269 · 2021: $189 · 2022: $524 · 2023: $525 · 2024: $521 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,788.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $502.76 | 2022-2025 | Mitraclip, Precision Xtra |
| Edwards Lifesciences Corporation | $478.19 | 2024-2025 | |
| Shockwave Medical, INC | $399.47 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $385.50 | 2019-2025 | Ilab Ultrasound Imaging System, General - Vascular Intervention |
| Medtronic, INC. | $338.38 | 2022-2025 | Symplicity G3 |
| Amgen INC. | $272.78 | 2019-2024 | Repatha |
| Astellas Pharma US INC | $221.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $189.90 | 2019-2021 | |
| Esperion Therapeutics, INC. | $133.96 | 2021-2022 | |
| Abiomed | $122.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $121.96 | 2019-2022 | |
| Amarin Pharma, INC. | $84.51 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.45 | 2019-2020 | |
| Medtronic Vascular, INC. | $56.08 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $42.06 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $38.62 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.18 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.82 | 2019-2021 | |
| Chiesi USA, INC. | $17.49 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.72 | 2019 | |
| Baylis Medical Company INC | $13.15 | 2021 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Condara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.